BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32562798)

  • 1. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
    Rai SK; Bril F; Hatch HM; Xu Y; Shelton L; Kalavalapalli S; Click A; Lee D; Beecher C; Kirby A; Kong K; Trevino J; Jha A; Jatav S; Kriti K; Luthra S; Garrett TJ; Guingab-Cagmat J; Plant D; Bose P; Cusi K; Hromas RA; Tischler AS; Powers JF; Gupta P; Bibb J; Beuschlein F; Robledo M; Calsina B; Timmers H; Taieb D; Kroiss M; Richter S; Langton K; Eisenhofer G; Bergeron R; Pacak K; Tevosian SG; Ghayee HK
    Metabolism; 2020 Sep; 110():154297. PubMed ID: 32562798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
    BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
    Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
    Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene.
    Oishi Y; Nagai S; Yoshida M; Fujisawa S; Sazawa A; Shinohara N; Nonomura K; Matsuno K; Shimizu C
    Endocr J; 2010; 57(8):745-50. PubMed ID: 20505258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
    Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
    Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Characterization and Glyceraldehyde-3-Phosphate Dehydrogenase-Dependent Regulation of Epithelial Sodium Channels in hPheo1 Wild-type and SDHB Knockdown Cells.
    Bala N; Yu L; Liu LP; Shelton L; Xu Y; Ghayee HK; Alli AA
    Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36763043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas.
    Ghayee HK; Giubellino A; Click A; Kapur P; Christie A; Xie XJ; Martucci V; Shay JW; Souza RF; Pacak K
    Eur J Clin Invest; 2013 Sep; 43(9):970-7. PubMed ID: 23889685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.
    Matro J; Giubellino A; Pacak K
    Horm Metab Res; 2013 Feb; 45(2):147-53. PubMed ID: 23322515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Succinate Mediates Tumorigenic Effects
    Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
    Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.
    Timmers HJ; Gimenez-Roqueplo AP; Mannelli M; Pacak K
    Endocr Relat Cancer; 2009 Jun; 16(2):391-400. PubMed ID: 19190077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas.
    Castelblanco E; Santacana M; Valls J; de Cubas A; Cascón A; Robledo M; Matias-Guiu X
    Endocr Pathol; 2013 Dec; 24(4):199-205. PubMed ID: 24096807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
    Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
    Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NAD
    Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
    Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
    [No Abstract]   [Full Text] [Related]  

  • 19. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
    Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
    JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.